Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 19/20 | 0.75 |
| ▸ | GSK3B | P49841 | 12/20 | 0.75 |
| ▸ | PRKACA | P17612 | 11/20 | 0.60 |
| ▸ | HIPK2 | Q9H2X6 | 11/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.60 |
| ▸ | PIM1 | P11309 | 10/20 | 0.60 |
| ▸ | CDK2 | P24941 | 10/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 6/20 | 0.60 |
| ▸ | PAK4 | O96013 | 6/20 | 0.60 |
| ▸ | PRKX | P51817 | 6/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.60 |
| ▸ | CDK9 | P50750 | 6/20 | 0.60 |
| ▸ | MELK | Q14680 | 5/20 | 0.60 |
| ▸ | CDK8 | P49336 | 5/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.60 |
| ▸ | STK3 | Q13188 | 5/20 | 0.60 |
| ▸ | MINK1 | Q8N4C8 | 5/20 | 0.60 |
| ▸ | MAP4K5 | Q9Y4K4 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045143 | 1.00 | CDC7 (0.75) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL1047053 | 0.91 | CDC7 (0.73) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL15190070 | 0.89 | CDC7 (0.70) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL6127299 | 0.89 | CDC7 (0.72) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL1043075 | 0.88 | CDC7 (0.74) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL1043078 | 0.88 | CDC7 (0.74) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL15190316 | 0.87 | CDC7 (0.82) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL1045417 | 0.87 | CDC7 (0.82) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL1046067 | 0.87 | CDC7 (0.94) | CDC7GSK3BPRKACAHIPK2ROCK2 | |
| SCHEMBL1046147 | 0.87 | CDC7 (0.72) | CDC7GSK3BPRKACAHIPK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | claimed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | claimed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | claimed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | claimed |
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | CDC7 1/4885GSK3B 442/4885PRKACA 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.